Teva Pharmaceutical Industries Ltd. provided earnings guidance for the year ending December 31, 2017. For the year, the company expects net revenues to be in the range of $23.8 billion to $24.5 billion, gross profit expected to be in the range of 57% to 58%, operating income expected to be in the range of $7.4 billion to $7.8 billion, tax expected to be in the range of 17% to 18%, EPS expected to be in the range of $4.90 to $5.30, cash flow from operations expected to be in the range of $5.7 billion to $6.1 billion and free cash flow expected to be in the range of $6.3 billion to $6.7 billion.